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Dear Editor, 
Opsoclonus-myoclonus syndrome (OMS) is a rare neuroinflammatory disease of 
paraneoplastic, parainfectious or idiopathic origin, characterized by opsoclonus, myoclonus, 
ataxia, as well as behavioral and sleep disorders. OMS is a rare disorder that appears in 1 in a 
million individuals worldwide. It usually affects infants and young children. In approximately 
50 percent of affected children, a tumor of embryonic nerve cells (neuroblastoma) is responsible 
for the symptoms associated with OMS. In other cases, the disorder has been designated 
„idiopathic“ or attributed to various mostly viral infections (Coxsackie virus B3 or St. Louis 
encephalitis virus) or bacterial infections (Streptococcus) [1, 2]. We present a case of a 22-year 
old girl  that was admitted to our hospital due to opsoclonus with rapid, involuntary, horizontal 
and vertical, conjugate fast eye movements, mild myoclonic jerks of eyelids, upper and 
lower limbs, and mild ataxia. Extensive diagnostic evaluation was performed. Her routine 
investigations of laboratory tests, including thyroid hormones were normal. Erythrocyte 
sedimentation rate, C-reactive protein and other immunological tests (antinuclear antibody, 
antineutrophil cytoplasmic antibodies, anti-dsDNA antibodies, C3 and C4-complement, 
serum immunoelectrophoresis) were negative, as well as oncomarkers, paraneoplastic and 
antiganglioside antiboidies. Swab of the posterior pharynx revealed  Streptococcus pyogenes 
(group A). Patient did not have signs of pharyngitis. Antistreptolysin O (ASO) titer was 653 
IU/ml. Tests for detection of viral markers for cytomegalovirus, Epstein‐Barr virus, herpes 
simplex viruses type 1 and 2, varicella-zoster virus, human immunodeficiency virus, hepatitis 
B and C virus were negative. Molecular-genetic analysis for spinocerebellar ataxia type 1, 2, 3, 
6, and 7, MELAS (mitochondrial myopathy, encephalopathy lactic acidosis, and stroke-like) 
syndrome, myoclonic epilepsy with ragged red fibers, Unverricht-Lundborg disease (EPM1) 
and Lafora disease (EPM2A or EPM2B) was normal. Anti-neuroleukin antibodies, urinary 
vanillymandelic acid and homovanillic acid were not determined in our patient. Anti-Ri and 
anti-Hu antibodies were negative. Cerebrospinal fluid analysis was within normal limits. 
Electroencephalogram showed right tempoparietal lateralisation and left focal abnormalities 
with occasional generalized spike-and-wave discharges. Brain magnetic resonance imaging 3-
Tesla was normal. Positron emission tomography showed increased glucose metabolism in the 
tonsils and sublingual glands. Electromyoneurography  found a mild sensory polyneuropathy. 
Following diagnostic evaluation, we have made the diagnosis of poststreptococcal OMS and 
administered intravenous immunoglobulin (IVIG) at  doses of 0.4 g/kg given on 5 consecutive 
days, with oral penicillin V for 10 days and then intramuscular benzathine penicillin G, which 
resulted in clinical improvement and gradual normalization of neurological status. We have 
also started antiepileptic therapy with levetiracetam and clonazepam. The treatment of IVIG 
continued till today once a month, with remission of the disease. Intramuscular benzathine 
penicillin G was introduced every month for a year. Two years since the beginning of the 
treatment, the ASO titer decreased (304 IU/ml). Five years since the beginnig of  the treatment, 
the disease is still in remission.  
The immunopathogenesis of OMS is poorly understood. There appears to be humoral and cell-
mediated immune mechanisms involved both in paraneoplastic and idiopathic syndromes [3]. 
In many cases the symptoms are reversible after treatment with immunotherapy [3, 4]. Our 
patient presented with poststreptococcal OMS, with high ASO titer, but without signs of 
bacterial inflammation of the pharynx. She was much older than the typical patient with 
pediatric paraneoplastic OMS and much younger than the typical adult patient with 
paraneoplastic OMS. First two similar case reports of post‐streptococcal OMS were presented 
2006 by Candler et al, and they were associated with CSF anti-neuroleukin (NLK) 
antibodies. The antigen was identified as human neuroleukin (glucose‐6‐phosphate isomerase, 
GPI). GPI is present on the cell surface of streptococcus making the protein a candidate target 
for molecular mimicry. We suppose anti-neuroleukin antibodies were responsible for the 
immunopathogenesis of OMS in our patient.  The role of streptococcus in OMS and the 
frequency with which anti‐NLK responses occur should be investigated further [5]. 
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